Pieris Presents Preclinical Data for PRS-110 c-Met Antagonist Anticalin® at the AACR Annual Meeting
Chicago, Illinois (ots) - --Results Support Differentiating Drug-like Features for Targeted Anti-cancer Drug-- Pieris AG announced today the presentation of a range of in vitro and in vivo preclinical data for the company's proprietary c-Met antagonist program, PRS-110, at the American Association for Cancer ...
plus